China Universal Asset Management Co. Ltd. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,570 shares of the biotechnology company's stock after selling 3,187 shares during the

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AlphaQuest LLC decreased its position in shares of Biogen Inc. (NASDAQ: BIIB) by 96.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375 shares of the biotechnology company's stock after selling 10,789 shares during the quarter. AlphaQuest LLC's holdings in

Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair

Candriam S.C.A. lowered its stake in Biogen Inc. (NASDAQ: BIIB) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 158,821 shares of the biotechnology company's stock after selling 4,494 shares during the period. Candriam S.C.A. owned approximately 0.11%

State of Michigan Retirement System cut its stake in Biogen Inc. (NASDAQ: BIIB) by 85.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,103 shares of the biotechnology company's stock after selling 248,200 shares during the quarter. State of

Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings.

Biogen (BIIB) is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer's therapies, driving improved mix quality. BIIB's 2025 growth products generated $3.3B, offsetting MS declines; non-GAAP EPS exceeded guidance at $15.28, reflecting strong cost discipline and operational execution. Despite a guided mid-single-digit revenue decline in 2026, BIIB maintains robust earnings power, with key catalysts, including Leqembi expansion and potential high-dose Spinraza approval.

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates.